FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Merck | Vaccine | Zostavax | Shingles

Patients clamor for scarce Merck vaccine

Tools

High demand for Merck's Zostavax shingles vaccine is causing shortages across the country. Doctors are putting patients on waiting lists; some physicians report hundreds of people in line for the shot. And this despite the fact that the vaccine is approved just for patients 60-plus (Merck is testing it now for the 50- to 59-year-olds)

The drugmaker didn't expect demand for Zostavax to shoot up so quickly, but that's not the only reason why production is lagging. The shot uses the same base as the chicken pox vaccine, and Merck had had some trouble ginning up enough of that ingredient. Plus, the CDC recently recommended two chicken-pox shots for kids rather than just one.

Merck says the delays could continue for "the coming months." Providers who've ordered doses first were told they'd arrive in 12-15 weeks, but now the word is, "We're not sure," said one pharmacist.

- read the story in the Wichita Eagle

Related Articles:
One up, two down for Merck's vaccines
CDC backs wide use of Merck's Zostavax


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Vaccine   Zostavax   Shingles   Merck